Metabolism and enantioselective pharmacokinetics of Casodex in man
- 1 January 1993
- journal article
- research article
- Published by Taylor & Francis in Xenobiotica
- Vol. 23 (11) , 1241-1253
- https://doi.org/10.3109/00498259309059435
Abstract
1. Five healthy male volunteers received a single oral dose (50 mg; 42 microCi) of 14C-Casodex, a racemic compound, which has its antiandrogen activity predominantly in R-Casodex, the (-)-enantiomer, with little activity in S-Casodex, the (+)-enantiomer. 2. Plasma concentrations of R-Casodex increased slowly in all subjects to reach a peak of 559-970 ng/ml between 15 and 48 h after dosing and, thereafter, declined monoexponentially with a mean half-life of 4.2 days. Plasma concentrations of S-Casodex rose rapidly to reach a peak of 32-66 ng/ml within the first 2-5 h, and then declined monoexponentially with a mean half-life of 19 h. Plasma concentrations of the racemate were in very good agreement with the sum of the enantiomer concentrations throughout the study and were very similar to concentrations of total radioactivity over the first 4 days. 3. About 80% of the radioactive dose was recovered in urine (35.8 +/- 1.7%; mean +/- SEM) and faeces (42.6 +/- 2.9%) during a total collection over 9 days; this incomplete recovery was consistent with the slow elimination of R-Casodex. 4. T.l.c. of urine extracts indicated extensive metabolism of Casodex to two polar metabolites identified as the glucuronide conjugates of Casodex and hydroxy-Casodex; almost no parent compound was observed. Virtually all of the Casodex glucuronide excreted in urine during the first 2 days was derived from S-Casodex, consistent with the relatively low plasma concentrations and rapid elimination of this enantiomer. 5. T.l.c. of faecal extracts showed the presence of both Casodex and hydroxy-Casodex; these may have been eliminated in bile as the glucuronide conjugates, with subsequent hydrolysis in the intestinal tract.Keywords
This publication has 10 references indexed in Scilit:
- Metabolism of Casodex in laboratory animalsXenobiotica, 1993
- Modfit: A pharmacokinetics computer programBiopharmaceutics & Drug Disposition, 1990
- The Response of Advanced Prostatic Cancer to a New Non-Steroidal Antiandrogen: Results of a Multicenter Open Phase II Study of CasodexEuropean Urology, 1990
- The Pharmacokinetics of Casodex in Prostate Cancer Patients after Single and during Multiple DosingEuropean Urology, 1990
- A possible explanation for the peripheral selectivity of a novel non-steroidal pure antiandrogen, Casodex (ICI 176,334)British Journal of Cancer, 1989
- Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilidesJournal of Medicinal Chemistry, 1988
- The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatmentEuropean Journal of Clinical Pharmacology, 1988
- ICI 176,334: A NOVEL NON–STEROIDAL, PERIPHERALLY SELECTIVE ANTIANDROGENJournal of Endocrinology, 1987
- Percutaneous Penetration And Metabolism Of Topical [14C]Flutamide in MenJournal of Investigative Dermatology, 1976
- Disposition of a New, Nonsteroid, Antiandrogen, α,α,α-Trifluoro-2-methyl-4′-nitro-m-propionotoluidide (Flutamide), in Men Following a single Oral 200 mg DoseJournal of Clinical Endocrinology & Metabolism, 1975